Cannabis ETFs Rally as Federal Rescheduling Eases Industry Pressure
💡 Key Takeaway
The federal reclassification of marijuana to Schedule III marks a pivotal, profitability-enhancing shift for the cannabis industry, reviving investor interest in related ETFs.
A Watershed Week for Weed
This week, the U.S. Justice Department officially reclassified marijuana from Schedule I—a category for drugs like heroin with no accepted medical use—to the less restrictive Schedule III, which includes substances like testosterone and codeine. This historic move, driven by an executive order from President Trump, applies specifically to state-licensed medical cannabis and sets the stage for a June hearing to consider reclassifying recreational use as well.
The news triggered an immediate rally in cannabis-focused exchange-traded funds (ETFs). The AdvisorShares Pure U.S. Cannabis ETF (MSOS), which holds U.S.-focused operators, surged over 6%. The broader, globally-oriented Amplify Alternative Harvest ETF (MJ) also climbed more than 2%. However, gains were tempered as investors digested the incremental nature of the change, with some ETFs like AdvisorShares Pure Cannabis ETF (YOLO) giving back initial spikes.
This action is part of a broader push by the Trump administration to ease restrictions on certain drugs, following a recent order to speed up FDA reviews for psychedelics. The President has publicly criticized the pace of the cannabis rescheduling process, signaling a continued political will to reform drug policy.
From Regulatory Shackles to Financial Flexibility
This rescheduling is far more than a symbolic victory; it directly attacks two of the cannabis industry's biggest profitability killers. First, by moving cannabis off Schedule I, the path is cleared for companies to finally gain full access to the U.S. banking system and capital markets, which have been largely closed due to federal illegality. Second, it opens the door to repealing Section 280E of the tax code, which currently prevents cannabis businesses from deducting standard business expenses, crippling their bottom lines.
The winners are clear: U.S.-focused multi-state operators (MSOs) stand to gain the most, as they are directly burdened by these federal restrictions. ETFs like MSOS, which holds these domestic players, are a direct conduit for this thesis. The move also makes legalization more politically palatable at the state level, potentially expanding the total addressable market for both medical and recreational use.
However, the rally's moderation highlights that this is a step, not the finish line. Full recreational rescheduling is still pending, and the benefits of banking access and tax reform will take time to materialize. Investors in globally diversified funds like MJ and YOLO, which hold Canadian producers less affected by U.S. tax law, may see more muted, indirect benefits from increased overall sector sentiment and demand.
Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.
Bobby Insight
The sector's fundamental trajectory has decisively improved, making select cannabis ETFs a compelling, albeit volatile, speculative opportunity.
The rescheduling is a concrete, long-awaited catalyst that begins to dismantle the structural barriers to industry profitability. While the path forward remains incremental and political risk persists, the direction of regulatory travel is now unmistakably positive, setting the stage for a re-rating of companies that can now envision sustainable earnings.
What This Means for Me
